Life Sciences

  • July 31, 2026

    AI Drugmaker Investors Seek Final OK For $9.75M Fraud Deal

    A class of investors in the artificial intelligence-driven drugmaker BioXcel Therapeutics Inc. has moved for final approval of a $9.75 million settlement to resolve claims that the stock price plunged after the company's late disclosure of compliance problems with a clinical trial for an Alzheimer's drug, and class counsel is seeking around 25%.

  • July 31, 2026

    No Standing For NY 'Aid-In-Dying' Law Challenge, Judge Rules

    A New York federal judge tossed a challenge by disability rights organizations and individuals to a state law enacted this year allowing patients with terminal illnesses to seek a doctor's assistance in ending their lives, finding the group lacked standing.

  • July 31, 2026

    Just For Men Maker Says Insurers Must Cover Injury Deals

    The maker of Just For Men hair color products said in a new federal complaint that its excess liability insurers improperly refused to cover personal injury lawsuit settlements connected to allegations that products from the popular line permanently discolored users' faces, after millions in the company's primary policies were exhausted.

  • July 31, 2026

    Insulet Urges Full Fed. Circ. To Revive $59M Trade Secret Win

    Insulin product developer Insulet Corp. has asked the full Federal Circuit to hear its arguments for reinstating a jury's $59.4 million trade secret theft verdict against EOFlow Co. Ltd., saying a split panel decision overturning the award reached a timeliness issue that was not mentioned by either party.

  • July 30, 2026

    9th Circ. Reverses Hologenix CEO's Tortious Interference Loss

    A Ninth Circuit panel reversed a $2.5 million judgment Thursday against Hologenix CEO Seth Casden by finding a district court erred in ruling the executive is not immune from a tortious interference claim while also reversing a Lanham Act disgorgement award totaling nearly $3 million.

  • July 30, 2026

    NC, Green Groups Call EPA-Chemours PFAS Deal Too Lenient

    North Carolina state leaders and environmental organizations asked the federal government to walk back a proposed settlement with Chemours over so-called forever chemical pollution from three factories, saying the deal amounted to a slap on the wrist.

  • July 30, 2026

    Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row

    Health plans and pharmacies backed by Cigna are asking the Second Circuit to revive a proposed class action alleging Bristol-Myers Squibb Co. and its Celgene subsidiary fraudulently obtained patents, filed sham lawsuits and paid off generic-drug makers to maintain a monopoly on the blockbuster blood cancer drug Pomalyst.

  • July 30, 2026

    CBP Outlines Rates, Classifications For Pharma Tariffs

    U.S. pharmaceutical giants aren't expected to face various tariff rates up to 100% on certain imported patented drugs and ingredients beginning Friday, but all importers must begin to classify their goods that will eventually be subject to the duties, according to customs guidance published Thursday.

  • July 30, 2026

    Albertsons Can't Nix 14 Years Of Opioid Claims At Wash. Trial

    Albertsons and Safeway can't dodge 14 years' worth of claims in Washington state's lawsuit accusing the grocery stores' pharmacies of irresponsibly dispensing prescription opioids and fueling the state's overdose crisis, according to a Seattle judge's ruling Wednesday striking the companies' statute-of-limitations defense.

  • July 30, 2026

    Squires Erases PTAB Ax Of Dermatology IP Upheld At ITC

    U.S. Patent and Trademark Office Director John Squires has thrown out the Patent Trial and Appeal Board's finding that Biofrontera Inc. had shown that all the challenged claims of a Sun Pharmaceutical Industries Inc. patent on a photodynamic dermatology device are invalid as obvious.

  • July 30, 2026

    Curium, Sazerac And Stripe Pursue Megadeals, And More

    Reports of potential multibillion-dollar deals were plentiful this week, with U.S. alcohol producer Sazerac steadfast in its $15 billion pursuit of the maker of Jack Daniel's; Curium reportedly in advanced talks to acquire fellow radiopharmaceutical firm Lantheus Holdings Inc. for up to $8 billion; and Nvidia, Stripe and Devon Energy all linked to sizable strategic bets of their own.

  • July 30, 2026

    2nd Circ. Revives Decongestant 'Maximum Strength' Claims

    The Second Circuit on Thursday revived claims in multidistrict litigation alleging makers of oral decongestants misled consumers by labeling their products as "maximum strength," while finding the bulk of the remaining claims were preempted by federal regulation.

  • July 30, 2026

    Covidien Hid Mesh Risks, Bellwether Jury Told As Trial Ends

    Counsel for an Alabama man told a Massachusetts federal jury Thursday that Covidien LP failed to adequately warn doctors about the risks of complications from a hernia mesh implant, closing out the first bellwether trial among thousands of cases pending against the Medtronic unit.

  • July 30, 2026

    Squires Grants 6 Patent Petitions, Denies 4 In New Order

    U.S. Patent and Trademark Office Director John Squires has granted six requests for America Invents Act patent reviews and rejected four in his latest batch of decisions.

  • July 30, 2026

    J&J Pans Talc Claimant's 'Absurd' Bid To Nix $25M Appeal

    In a sharply worded memo, Johnson & Johnson told the Connecticut Appellate Court that it should deny a "nonsensical" dismissal motion from a real estate developer who won a $25 million asbestos-related cancer verdict, defending its appeal of the trial court outcome as timely.

  • July 30, 2026

    Pa. Paraquat, Gov. Shapiro's Neighbors: A Midyear Report

    Mass tort and antitrust cases advanced this year in Pennsylvania, where attorneys await Philadelphia's first paraquat trial and more developments in the class action against the Law School Admissions Council over test fees.

  • July 30, 2026

    2 Traders Admit Guilt In Stolen BigLaw Info Scheme

    Two men pled guilty Thursday in Massachusetts federal court to their roles in a sweeping scheme to trade on inside information stolen from huge corporate law firms about upcoming deals.

  • July 29, 2026

    Albertsons Pharmacy Work Was 'House Of Cards,' Judge Told

    Albertsons pharmacists in Washington state repeatedly warned supervisors that busy workloads and limited staffing were making it difficult to review prescriptions before filling them, a state judge in Seattle heard Monday, during a bench trial in Washington's case accusing Albertsons and its Safeway subsidiary of fueling the state's opioid crisis.

  • July 29, 2026

    2nd Circ. Backs Ex-Shkreli Atty's 401(k) Restitution Deal

    A New York trial judge erred in rejecting a retirement-fund garnishment deal that would have protected Martin Shkreli's convicted former lawyer from tax penalties, the Second Circuit ruled Wednesday.

  • July 29, 2026

    Novo Faces Narrowed Investor Suit Over Obesity Drug Claims

    A New Jersey federal judge narrowed a proposed securities class action against Novo Nordisk, preserving claims that it misled investors about the CagriSema obesity drug's tolerability and a flexible protocol used in a clinical trial.

  • July 29, 2026

    Depo-Provera MDL Gets New Lead Plaintiffs After Settlement

    The Florida federal judge overseeing the multidistrict litigation over a link between brain tumors and the hormonal contraceptive Depo-Provera on Wednesday approved three new pilot plaintiffs for the cases remaining after a global settlement that the judge called an "excellent outcome."

  • July 29, 2026

    Curaleaf Says Pot Suit Is Long On Length But Not Substance

    Cannabis giant Curaleaf Holdings Inc. on Tuesday slammed as "ill-conceived" a proposed class action by consumers who claim the company falsely marketed its products as medical treatments for mental health disorders and physical pain, saying none of the buyers are even medical cannabis patients.

  • July 29, 2026

    FTC Says Hims & Hers Shares Health Data, Misleads Users

    The Federal Trade Commission and regulators in California and Utah allege in a federal lawsuit filed Wednesday that Hims & Hers promises patient privacy while actually sharing consumers' sensitive health information with Meta Platforms and other third-party advertising platforms and that the telehealth provider has deceived users about its billing practices.

  • July 29, 2026

    Colo. Hospital Patients In Gender Care Suit Seek Class Cert.

    Transgender adolescents urged a Colorado state judge Wednesday to allow them to proceed as a certified class in their lawsuit seeking to have Children's Hospital Colorado resume providing gender-affirming care for them and other transgender youth patients, arguing the class is "objectively definable."

  • July 29, 2026

    9th Circ. Revives Biotech Worker's Pension Plan Suit

    The Ninth Circuit reopened a former Calbiotech Inc. scientist's lawsuit claiming the company unlawfully hid the existence of a pension plan, saying a trial court erred in concluding that a document specifying who was eligible to participate in the plan was legitimate.

Expert Analysis

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

  • 2 Discovery Rulings Break With Heppner On AI Privilege Issue

    Author Photo

    While a New York federal court’s recent ruling in U.S. v. Heppner suggests that some litigants’ communications with AI tools are discoverable, two other recent federal court decisions demonstrate that such interactions generally qualify for work-product protection under the Federal Rules of Civil Procedure, says Joshua Dunn at Brown Rudnick.

  • Series

    Isshin-Ryu Karate Makes Me A Better Lawyer

    Author Photo

    My involvement in martial arts, specifically Isshin-ryu, which has principles rooted in the eight codes of karate, has been one of the most foundational in the development of my personality, and particularly my approach to challenges — including in my practice of law, says Kaitlyn Stone at Barnes & Thornburg.

  • Microplastics On Water Contaminant List Could Spur Claims

    Author Photo

    The U.S. Environmental Protection Agency's proposal to include microplastics in its draft sixth Contaminant Candidate List under the Safe Drinking Water Act could influence consumer fraud claims and enforcement by state attorneys general, as well as claims against manufacturers from entities facing regulatory compliance costs, says Arie Feltman-Frank at Jenner & Block.

  • USPTO's AI Search Pilot May Reshape Patent Filing Strategy

    Author Photo

    The U.S. Patent and Trademark Office's new artificial intelligence search pilot aims to introduce earlier visibility into the prior art landscape, potentially influencing patent filing considerations and shifting the role of counsel to an earlier stage of the prosecution process, say attorneys at Foley & Lardner.

  • Peptide Policy Is Shifting Toward Sanctioned Compounding

    Author Photo

    The policy landscape for peptides is undergoing a significant shift under the Trump administration, moving toward a complex system of verified compounding and complementary enforcement that will likely bring peptides firmly back into the sphere of legitimate consumer products, say attorneys at Sheppard.

  • Keys To Building Defensible Psychedelic Therapy Programs

    Author Photo

    Given the rapidly evolving legal environment for psychedelic therapies and heightened liability and compliance risks facing providers, meticulous documentation, robust risk management protocols, and proactive engagement with professional organizations and insurers are essential strategies, say Kimberly Chew at Husch Blackwell and L. Alison McInnes at Mindful Health Solutions.

  • Opinion

    State Bars Need To Get Specific About AI Confidentiality

    Author Photo

    Lawyers need to put actual client information into artificial intelligence tools to get their full value, but they cannot confidently do so until state bars offer clear, formal authority on which plan tiers of the three most popular generative AI tools are safe to use when sharing specific client details, says attorney Nick Berk.

  • Series

    Alpine Skiing Makes Me A Better Lawyer

    Author Photo

    Skiing has shaped habits I rely on daily as an attorney — focus, resilience and the ability to remain steady when circumstances shift rapidly — and influences the way I approach legal strategy, client counseling and teamwork, says Isaku Begert at Marshall Gerstein.

  • FDA Guidance May Move Goalposts For Form 483 Responses

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration provides formal insight on how drug manufacturers are expected to respond to Form 483s, raising some concerns about the agency's timelines and expectations, say attorneys at Cooley.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.